Results 151 to 160 of about 136,011 (340)

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Cancer Reports
Objective To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab. Methods We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to ...
Kunpeng Fang, Jie Wang, Jianyong Yuan, Chengjun Sui, Jiajun Zhi, Yong Xia, Minmin Sun   +6 more
doaj   +1 more source

Death of human tumor endothelial cells in vitro through a probable calcium-associated mechanism induced by bevacizumab and detected via a novel method [PDF]

, 2010
We isolated three dimensional cell clusters from fresh human solid tumors and also isolated human neoplastic and normal lymphatic cells. Cells were cultured for 96 hours with and without bevacizumab and other agents.
Constance Rueff-Weisenthal, Haddy Liu, Larry Weisenthal   +2 more
core   +1 more source

FDA Approval Summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.

The Oncologist, 2020
On December 19, 2018, the Food and Drug Administration (FDA) granted approval to olaparib monotherapy for first-line maintenance treatment of BRCA mutated (BRCAm) advanced ovarian cancer and on May 8, 2020, expanded the indication of olaparib to include ...
Shaily Arora, S. Balasubramaniam, Hui Zhang, T. Berman, P. Narayan, D. Suzman, E. Bloomquist, Shenghui Tang, Y. Gong, R. Sridhara, Francisca Reyes Turcu, D. Chatterjee, Banu Saritas-Yildirim, Soma Ghosh, Reena Philip, A. Pathak, Jennifer J. Gao, L. Amiri-Kordestani, R. Pazdur, J. Beaver   +19 more
semanticscholar   +1 more source

Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?

Thoracic Cancer, Volume 13, Issue 24, Page 3504-3509, December 2022., 2022
Forty‐nine patients developed febrile neutropenia (FN) during 813 courses of lung cancer chemotherapy; 12 patients were unable or declined to resume chemotherapy even after recovery of infection and nine of them died within 90 days. The MASCC and CISNE scores, widely used to predict the risk of severe medical complications during FN, were also useful ...
Yoshitaka Ono, Naoki Hayama, Shigeaki Hattori, Yoko Ito, Tsuyoshi Oguma, Fumio Sakamaki, Koichiro Asano   +6 more
wiley   +1 more source

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

Cancer Medicine, 2019
Purpose Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear.
Hung‐Chih Hsu, Yu‐Chun Liu, Chuang‐Wei Wang, Wen-Chi Chou, Yu-Jen Hsu, Jy-Ming Chiang, Yung-Chang Lin, Tsai-Sheng Yang   +7 more
doaj   +1 more source

Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study [PDF]

arXiv, 2019
Existing trials had not taken enough consideration of their population representativeness, which can lower the effectiveness when the treatment is applied in real-world clinical practice. We analyzed the eligibility criteria of Bevacizumab colorectal cancer treatment trials, assessed their a priori generalizability, and examined how it affects patient ...
arxiv  

Weekly versus three weeks chemotherapy for advanced ovarian cancer. A meta-analysis [PDF]

, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear.
De Felice, Francesca, Marchetti, Claudia, Monti, Marco, Musella, Angela, Musio, Daniela, Muzii, Ludovico, Palaia, Innocenza, Panici, Pierluigi Benedetti, Tombolini, Vincenzo   +8 more
core   +1 more source

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer

Thoracic Cancer, Volume 14, Issue 1, Page 91-104, January 2023., 2023
To improve the diagnosis and treatment of HER2‐altered non‐small cell lung cancer in China, we reached consensus on detection strategy based on alteration type, sample selection, detection method, quality control, and treatment suggestion. Moreover, we systematically reviewed the clinical efficacy, resistance mechanisms, and development status of HER2‐
Shirong Zhang, Wenxian Wang, Chunwei Xu, Yongchang Zhang, Xiuyu Cai, Qian Wang, Zhengbo Song, Ziming Li, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Jingjing Liu, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Jingping Yuan, Zhansheng Jiang, Xingxiang Pu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Weiwei Pan, Xiaowei Dong, Fei Pang, Kai Wang, Chao Yao, Guomin Lin, Site Li, Zhi Yang, Jiancheng Luo, Hongtao Jia, Xiuqing Nie, Liping Wang, Youcai Zhu, Xiao Hu, Yanru Xie, Xinqing Lin, Jing Cai, Yang Xia, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jing Kang, Jiatao Zhang, Chao Zhang, Wenbin Gao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Bing Wan, Donglai Lv, Genhua Yu, Lin Shi, Yuanli Xia, Feng Gao, Xiaochen Zhang, Tao Xu, Wei Zhou, Haixia Wang, Zhefeng Liu, Nong Yang, Lin Wu, Qiming Wang, Guansong Wang, Zhuan Hong, Jiandong Wang, Meiyu Fang, Yong Fang, Yiping Zhang, Yong Song, Shenglin Ma, Wenfeng Fang, Yuanzhi Lu   +98 more
wiley   +1 more source

Regulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case study [PDF]

, 2015
Acknowledgements Professor Elizabeth Roughead is funded by a Future Fellowship from the Australian Research Council. The views expressed are those of the authors, the sponsor had no role in the preparation of the manuscript.Peer reviewedPublisher ...
Entwistle, Vikki, Nguyen, Tuan, Roughead, Elizabeth, Vitry, Agnes   +3 more
core   +1 more source

A Comprehensive Review on Capillary Electrophoresis–Mass Spectrometry in Advancing Biomolecular Research

ELECTROPHORESIS, EarlyView.
ABSTRACT This review provides an in‐depth exploration of capillary electrophoresis–mass spectrometry (CE–MS) in biomolecular research from 2020 to 2024. CE–MS emerges as a versatile and powerful tool due to its numerous advantages, facilitating the analysis of various biomolecules, including proteins, peptides, oligonucleotides, and other metabolites ...
Laura Pont, María Vergara‐Barberán, Enrique Javier Carrasco‐Correa   +2 more
wiley   +1 more source